Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: An open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone

Human Psychopharmacology

Volumn 23, Issue 6, 2008, Pages 455-463

  Suzuki, Takefumi ^a   Uchida, Hiroyuki ^a,b   Watanabe, Koichiro ^a   Nakajima, Shinichiro ^a   Nomura, Kensuke ^a   Takeuchi, Hiroyoshi ^a   Tanabe, Akira ^c   Yagi, Gohei ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Antipsychotic polypharmacy; Olanzapine; Open label clinical trial; Risperidone; Treatment refractory schizophrenia

Indexed keywords

BIPERIDEN; BROTIZOLAM; CHOLESTEROL; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SULPIRIDE; VALPROIC ACID; ZOTEPINE;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; MALE; MONOTHERAPY; OPEN STUDY; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; RISPERIDONE; SCHIZOPHRENIA;

EID: 51049098290     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.959     Document Type: Article

References (38)

1. Akdede BB, Anil Yagcioglu AE, Alptekin K, et al. 2006. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 67: 1912-1919.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association. Washington, DC.
3. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. 2005. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66: 63-72.
4. Barbui C, Nose M, Mazzi MA, et al. 2006. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21: 355-362.
5. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. 2001. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 158: 518-526.
6. Chan J, Sweeting M. 2007. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 21: 657-664.
7. Correll CU, Frederickson AM, Kane JM, Manu P. 2007. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 89: 91-100.
8. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. 2008. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of the randomized controlled trials. Schizophr Bull 0:sbn018v2-sbn018.
9. Expert Consensus Guideline Series. 2003. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 64 (Suppl 12): 92-97.
10. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J. 2005. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5: 26.
11. Freudenreich O, Goff DC. 2002. Antipsychotic combination therapy in schizophrenia. A. review of efficacy and risks of current combinations. Acta Psychiatr Scand 106: 323-330.
12. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. 2004. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 65: 1377-1388.
13. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education and Welfare. Washington DC; 217-222.
14. Honer WG, Thornton AE, Chen EY, et al. 2006. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354: 472-482.
15. Hori H, Noguchi H, Hashimoto R, et al. 2006. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 86: 138-146.
16. Inada T, Yagi G, Miura S. 2002. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 57: 227-238.
17. Jones PB, Barnes TR, Davies L, et al. 2006. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079-1087.
18. Josiassen RC, Joseph A, Kohegyi E, et al. 2005. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162: 130-136.
19. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. 2006. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188: 122-127.
20. Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A. double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796.
21. Kapur S, Mamo D. 2003. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090.
22. Keefe RS, Bilder RM, Davis SM, et al. 2007. Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633-647.
23. Lerner V, Libov I, Kotler M, Strous RD. 2004. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 28: 89-98.
24. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
25. McEvoy JP, Lieberman JA, Stroup TS, et al. 2006. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600-610.
26. Miller AL, Hall CS, Buchanan RW, et al. 2004. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 65: 500-508.
27. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
28. Potter WZ, Ko GN, Zhang LD, Yan WW. 1989. Clozapine in China: A review and preview of US/PRC collaboration. Psychopharmacology (Berl) 99 (Suppl): S87-S91.
29. Remington G, Saha A, Chong SA, Shammi C. 2005. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19: 843-872.
30. Shiloh R, Zemishlany Z, Aizenberg D, et al. 1997. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171: 569-573.
31. Sim K, Su A, Fujii S, et al. 2004. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58: 178-183. Erratum in: Br J Clin Pharmacol 2004;58:564.
32. Stahl SM. 2004. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 7: 113-116.
33. Stahl SM, Grady MM. 2004. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11: 313-327.
34. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. 2004a. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 361-369.
35. Suzuki T, Uchida H, Tanaka KF, et al. 2004b. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7: 133-142.
36. Suzuki T, Uchida H, Watanabe K, et al. 2007. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting-. Psychopharmacology (Berl) 195: 285-295.
37. Waddington JL, Youssef HA, Kinsella A. 1998. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173: 325-329.
38. Zink M. 2005. Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci 30: 409-415.